^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + oleclumab (MEDI9447) (CD73 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFRm Non-Small-Cell Lung Cancer: A Brief Report
Published date:
01/11/2023
Excerpt:
This phase Ib/II study (NCT03381274) evaluated the anti-CD73 antibody oleclumab plus the third-generation EGFR TKI osimertinib in advanced EGFR-mutated NSCLC….In patients who were T790M-negative in tumor and ctDNA, ORR was 25.0% at DL1 and 11.8% at DL2 (all partial responses); response durations at DL2 were 14.8 and 16.6 months....Oleclumab plus osimertinib showed evidence of moderate activity with acceptable tolerability in previously treated patients with advanced EGFR-mutated NSCLC.
DOI:
https://doi.org/10.1016/j.jtho.2022.12.021
Trial ID:
